macrogol 4000: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
macrogol 4000: clinical details
Prescribing considerations
- Exclude an organic cause where clinically indicated, particularly in children or unexplained persistent constipation.
- Use as an adjunct to suitable dietary, hydration, activity and bowel-habit measures.
- Consider possible reduced absorption of concurrently administered oral medicines with a narrow therapeutic index.
- Sulphur dioxide in the apple flavour can rarely cause severe hypersensitivity or bronchospasm.
Contraindications and cautions
- Hypersensitivity to macrogol 4000 or any excipient
- Severe inflammatory bowel disease or toxic megacolon associated with symptomatic stenosis
- Gastrointestinal perforation or risk of perforation
- Ileus or suspected intestinal obstruction
- Painful abdominal syndrome of undetermined cause
Monitoring
- If diarrhoea develops, consider fluid and electrolyte assessment in older people, those with hepatic or renal impairment, and people taking diuretics.
- Investigate persistent symptoms or constipation accompanied by unexplained pain, fever or abdominal swelling.
Clinical pharmacology
Macrogol 4000 is an osmotically acting, high-molecular-weight polyethylene glycol. It retains water within the intestinal lumen and undergoes negligible gastrointestinal absorption or biotransformation.
Formulation and product differences
- The selected product is an apple-flavoured powder for oral solution containing macrogol 4000 without added electrolyte salts.
- It contains saccharin sodium and sulphur dioxide within the flavouring.
- It contains less than 1 mmol sodium per sachet and is described as essentially sodium-free.
- It contains a non-significant amount of sugar or polyol.
macrogol 4000 preparations and strengths
Oral solution
Route: Oral
Strengths: 10 g
macrogol 4000 interactions
Faster gastrointestinal transit may temporarily reduce absorption of other oral medicines. This matters most for medicines where small changes in exposure can affect safety or effectiveness.
Antiepileptic medicines
Absorption and seizure control could be affected; concurrent use should be reviewed by a pharmacist or prescriber.
Digoxin
Reduced absorption could alter its therapeutic effect, so concurrent use warrants professional review.
Immunosuppressants
Reduced absorption may lessen treatment exposure; check administration instructions with the specialist team or pharmacist.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.